Evidence map›Paper›PMID 23103493›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2013

Marine n3 polyunsaturated fatty acids enhance resistance to mitochondrial permeability transition in heart failure but do not improve survival.

Tatiana F Galvao, Ramzi J Khairallah, Erinne R Dabkowski, Bethany H Brown, Peter A Hecker, Kelly A O'Connell, Karen M O'Shea, Hani N Sabbah, Sharad Rastogi, Caroline Daneault and 2 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Mitochondrial CaJournal of molecular and cellular cardiology · 2021
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Effect of a high-protein diet on development of heart failure in response to pressure overload.Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 2014
    Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Tatiana F GalvaoDivision of Cardiology, Department of Medicine, University of Maryland, 20 Penn St., Baltimore, MD 21201, USA.
Ramzi J Khairallah
Erinne R Dabkowski
Bethany H Brown
Peter A Hecker
Kelly A O'Connell
Karen M O'Shea
Hani N Sabbah
Sharad Rastogi
Caroline Daneault
Christine Des Rosiers
William C Stanley
University of Maryland, Baltimore · USHenry Ford Hospital · USMontreal Heart Institute · CAUniversité de Montréal · CA

Funding

Substrate Selection and Oxidative Stress in Heart FailureP01HL074237 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI STANLEY, WILLIAM C · 2003 to 2013
$19.9M
Interdisciplinary Training Program Muscle BiologyT32AR007592 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI Aikaterini Kontrogianni-Konstantopoulos · 1996 to 2026
$11.7M
JHU-UMD Diabetes Research CenterP30DK079637 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WONDISFORD, FREDRIC E. · 2013 to 2017
$9.7M
Training Grant in Cardiac and Vascular Cell BiologyT32HL072751 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI FISHER, STEVEN A. · 2003 to 2013
$3.1M
Docosahexaenoic Acid for Treatment of Heart FailureP20HL101434 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI MEHRA, MANDEEP R, STANLEY, WILLIAM C · 2010 to 2011
$1.3M
NHLBI NIH HHS HL-072751NHLBI NIH HHS HL-074237NHLBI NIH HHS HL-101434NIAMS NIH HHS T32 AR007592NIDDK NIH HHS P30 DK079637
6 · The paper itself

Abstract

Mitochondrial dysfunction in heart failure includes greater susceptibility to mitochondrial permeability transition (MPT), which may worsen cardiac function and decrease survival. Treatment with a mixture of the n3 polyunsaturated fatty acids (n3 PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) is beneficial in heart failure patients and increases resistance to MPT in animal models. We assessed whether DHA and EPA have similar effects when given individually, and whether they prolong survival in heart failure. Male δ-sarcoglycan null cardiomyopathic hamsters were untreated or given either DHA, EPA, or a 1:1 mixture of DHA + EPA at 2.1% of energy intake. Treatment did not prolong survival: mean survival was 298 ± 15 days in untreated hamsters and 335 ± 17, 328 ± 14, and 311 ± 15 days with DHA, EPA, and DHA + EPA, respectively (n = 27-32/group). A subgroup of cardiomyopathic hamsters treated for 26 wk had impaired left ventricular function and increased cardiomyocyte apoptosis compared with normal hamsters, which was unaffected by n3 PUFA treatment. Evaluation of oxidative phosphorylation in isolated subsarcolemmal and interfibrillar mitochondria with substrates for complex I or II showed no effect of n3 PUFA treatment. On the other hand, interfibrillar mitochondria from cardiomyopathic hamsters were significantly more sensitive to Ca(2+)-induced MPT, which was completely normalized by treatment with DHA and partially corrected by EPA. In conclusion, treatment with DHA or EPA normalizes Ca(2+)-induced MPT in cardiomyopathic hamsters but does not prolong survival or improve cardiac function. This suggest that greater susceptibility to MPT is not a contributor to cardiac pathology and poor survival in heart failure.

Indexed as

AnimalsAnimals, Genetically ModifiedApoptosisCalciumCardiomyopathy, DilatedCardiotonic AgentsCricetinaeDisease Models, AnimalDocosahexaenoic AcidsDrug Therapy, CombinationEicosapentaenoic AcidHeart FailureMaleMitochondria, HeartMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreCalciumCardiotonic AgentsDocosahexaenoic AcidsEicosapentaenoic AcidMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PorePhospholipidsSarcoglycans

Identifiers

PMID23103493
PMCPMC3543685
OpenAlexW1984766889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.